血管生成
角膜新生血管
新生血管
化学
药理学
抗氧化剂
眼科
癌症研究
生物化学
医学
血管内皮生长因子受体
作者
Huimin Zhu,Jinfa Ye,Yiming Wu,Yujie Cheng,Min Su,Qixuan Dai,Yinuo Han,Jintao Pan,Zhenyu Wu,Chuan Chen,Chenyue Qiu,Wei Li,Gang Liu,Chengchao Chu
标识
DOI:10.1002/adhm.202302192
摘要
Abstract Corneal neovascularization (CNV) is one of the leading causes of blindness in the world. In clinical practice; however, it remains a challenge to achieve a noninvasive and safe treatment. Herein, a biocompatible shell with excellent antioxidant and antivascularity is prepared by co‐assembly of epigallocatechin gallate/gallic acid and Cu (II). After loading glucose oxidase (GO x ) inside, the shell is modified with dimeric DPA‐Zn for codelivering vascular endothelial growth factor (VEGF) small interfering RNA (VEGF‐siRNA). Meanwhile, the Arg‐Gly‐Asp peptide (RGD) peptide‐engineered cell membranes coating improves angiogenesis‐targeting and is biocompatible for the multifunctional nanomedicine (CEGs/RGD). After eye drops administration, CEGs/RGD targets enrichment in neovascularization and CEGs NPs enter cells. Then, the inner GO x consumes glucose with a decrease in local pH, which in turn leads to the release of EGCE and VEGF‐siRNA. As a result, the nanomedicines significantly reduce angiogenesis and inhibit CNV formation through synergistic effect of antioxidant and antivascular via down‐regulation of cluster of differentiation 31 and VEGF. The nanomedicine represents a safe and efficient CNV treatment through the combined effect of antioxidant/gene, which provides important theoretical and clinical significance.
科研通智能强力驱动
Strongly Powered by AbleSci AI